# Aurobindo Pharma receives USFDA approval for Valacyclovir HCl Tablets

25th May 2010

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration to manufacture and market Valacyclovir Hydrochloride Tablets 500mg (base) and 1g (base)

Valacyclovir Hydrochloride Tablets 500mg (base) and 1g (base) are the generic equivalent of GlaxoSmithKline's Valtrex® Caplets 500mg (base) and 1g (base). Valacyclovir Hydrochloride Tablets falls under the Anti-infective therapeutic category and is indicated for the treatment of cold sores, genital herpes and shingles in adult patients and chicken pox in pediatric patients 2-18 years of age. The product has a market size of approximately US$ 2 Billion according to Newport and is ready for launch.

Aurobindo now has a total of 117 ANDA approvals (87 Final approvals and 30 Tentative approvals) from USFDA

**About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

**For further information, please contact:**
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com